Explore
Trendline
Pfizer Secures Exclusive Rights to Starna Therapeutics' In Vivo CAR-T Programs for Autoimmune Diseases
Pfizer Secures Exclusive Rights to Starna Therapeutics' In Vivo CAR-T Programs for Autoimmune Diseases
Read More
Trendline
Bristol Myers Squibb Advances Neuroscience and Oncology Pipeline with New Late-Stage Projects
Bristol Myers Squibb Advances Neuroscience and Oncology Pipeline with New Late-Stage Projects
Read More
Trendline
Regeneron Pharmaceuticals Defies Skeptics with Strong Performance and Clinical Milestones
Regeneron Pharmaceuticals Defies Skeptics with Strong Performance and Clinical Milestones
Read More
Trendline
Moderna Raises 2026 Revenue Growth Outlook Amidst Personalized Cancer Vaccine Program Success and New Flu Vaccine Approval
Moderna Raises 2026 Revenue Growth Outlook Amidst Personalized Cancer Vaccine Program Success and New Flu Vaccine Approval
Read More
Trendline
Takeda Pharmaceutical Company Limited Collaborates with Nabla Bio and Other Firms on Pharmaceutical Development
Takeda Pharmaceutical Company Limited Collaborates with Nabla Bio and Other Firms on Pharmaceutical Development
Read More
Trendline
Sanofi Explores Potential $43 Billion Acquisition of Insmed Amidst Dupixent Patent Concerns
Sanofi Explores Potential $43 Billion Acquisition of Insmed Amidst Dupixent Patent Concerns
Read More
Trendline
Eli Lilly and Pfizer Compete for Pharmaceutical Market Dominance Amidst Shifting Growth Strategies
Eli Lilly and Pfizer Compete for Pharmaceutical Market Dominance Amidst Shifting Growth Strategies
Read More
Trendline
Sanofi Considers Acquisition of U.S. Drugmaker Insmed Inc. to Address Patent Cliff
Sanofi Considers Acquisition of U.S. Drugmaker Insmed Inc. to Address Patent Cliff
Read More
Trendline
Pfizer Enters Autoimmune CAR T Therapy Market with $2.6 Billion Deal with China's Starna Therapeutics
Pfizer Enters Autoimmune CAR T Therapy Market with $2.6 Billion Deal with China's Starna Therapeutics
Read More
Trendline
CRISPR Therapeutics Reports Positive Early Phase 1b Data for CTX310 and Zugo-Cel in Major Markets
CRISPR Therapeutics Reports Positive Early Phase 1b Data for CTX310 and Zugo-Cel in Major Markets
Read More
Trendline
Pfizer CEO Albert Bourla Warns of Chinese Biotech Threat, Advocates AI for Efficiency
Pfizer CEO Albert Bourla Warns of Chinese Biotech Threat, Advocates AI for Efficiency
Read More
Trendline
Novartis CEO Addresses Investor Concerns Over Patent Expirations with Pipeline Surge
Novartis CEO Addresses Investor Concerns Over Patent Expirations with Pipeline Surge
Read More